Giuseppe Toffoli

Summary

Affiliation: Centro di Riferimento Oncologico
Country: Italy

Publications

  1. ncbi request reprint Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase
    G Toffoli
    Unit of Experimental and Clinical Pharmacology, CRO National Cancer Institute, Aviano PN, Italy
    Int J Biol Markers 18:218-21. 2003
  2. ncbi request reprint Clinical implications of genetic polymorphisms on stomach cancer drug therapy
    G Toffoli
    Experimental and Clinical Pharmacology, CRO National Cancer Institute, Aviano, Italy
    Pharmacogenomics J 7:76-80. 2007
  3. ncbi request reprint Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano PN, Italy
    Clin Cancer Res 9:743-8. 2003
  4. ncbi request reprint Pharmacogenetics of irinotecan
    G Toffoli
    Experimental and Clinical Pharmacology, Unit CRO National Cancer Institute, 33081 Aviano PN, Italy
    Curr Med Chem Anticancer Agents 3:225-37. 2003
  5. ncbi request reprint Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy
    G Toffoli
    Experimental and Clinical Pharmacology, CRO National Cancer Institute, Via Pedemontana Occidentale 12, 33081 Aviano, Italy
    J Chemother 16:31-5. 2004
  6. ncbi request reprint Pharmacokinetic optimisation of treatment with oral etoposide
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Clin Pharmacokinet 43:441-66. 2004
  7. ncbi request reprint Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin
    G Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute 33081 Aviano PN, Italy
    J Chemother 16:193-200. 2004
  8. ncbi request reprint Pharmacogenomics and stomach cancer
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology, CRO National Cancer Institute, Via Pedemontana Occidentale, 12, 33081 Aviano, Italy
    Pharmacogenomics 5:627-41. 2004
  9. ncbi request reprint Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma
    G Toffoli
    Experimental and Clinical Pharamcology Unit, National Cancer Institute, Aviano, Italy
    Ann Oncol 15:1805-9. 2004
  10. ncbi request reprint Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Int J Cancer 103:294-9. 2003

Collaborators

Detail Information

Publications79

  1. ncbi request reprint Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase
    G Toffoli
    Unit of Experimental and Clinical Pharmacology, CRO National Cancer Institute, Aviano PN, Italy
    Int J Biol Markers 18:218-21. 2003
    ..These results indicate that MTHFR variants are not related to DLBCL development and MGMT hypermethylation...
  2. ncbi request reprint Clinical implications of genetic polymorphisms on stomach cancer drug therapy
    G Toffoli
    Experimental and Clinical Pharmacology, CRO National Cancer Institute, Aviano, Italy
    Pharmacogenomics J 7:76-80. 2007
  3. ncbi request reprint Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano PN, Italy
    Clin Cancer Res 9:743-8. 2003
    ..The aim of the study was to investigate the role of MTHFR 677 C-->T gene polymorphism in the tumorigenesis of proximal and distal CLC in a monoinstitutional group of patients in North Italy...
  4. ncbi request reprint Pharmacogenetics of irinotecan
    G Toffoli
    Experimental and Clinical Pharmacology, Unit CRO National Cancer Institute, 33081 Aviano PN, Italy
    Curr Med Chem Anticancer Agents 3:225-37. 2003
    ..In this review, we summarise the new developments on the study of the pharmacogenetics of irinotecan, stressing its importance in drug cytotoxic effect...
  5. ncbi request reprint Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy
    G Toffoli
    Experimental and Clinical Pharmacology, CRO National Cancer Institute, Via Pedemontana Occidentale 12, 33081 Aviano, Italy
    J Chemother 16:31-5. 2004
    ..Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate cycle, presenting two common polymorphisms (677C>T and 1298 A>C) which have impact on toxicity and efficacy of methotrexate and 5-fluorouracil...
  6. ncbi request reprint Pharmacokinetic optimisation of treatment with oral etoposide
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Clin Pharmacokinet 43:441-66. 2004
    ..However, they lack precision and accuracy and need to be refined by considering other predictor variables in order to extend their application in current clinical practice...
  7. ncbi request reprint Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin
    G Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute 33081 Aviano PN, Italy
    J Chemother 16:193-200. 2004
    ..Based on these results we were able to estimate that equiactive plasma drug exposure was reached with an approximately 2.5-fold greater oral dose/m2 of IDA than the corresponding i.v. dose...
  8. ncbi request reprint Pharmacogenomics and stomach cancer
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology, CRO National Cancer Institute, Via Pedemontana Occidentale, 12, 33081 Aviano, Italy
    Pharmacogenomics 5:627-41. 2004
    ....
  9. ncbi request reprint Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma
    G Toffoli
    Experimental and Clinical Pharamcology Unit, National Cancer Institute, Aviano, Italy
    Ann Oncol 15:1805-9. 2004
    ..To ascertain the cause of increased toxicity, we investigated the pharmacokinetics of DOX in HIV-patients with NHL treated with CHOP with and without HAART...
  10. ncbi request reprint Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Int J Cancer 103:294-9. 2003
    ..0004). In conclusion, our data suggest that the TT MTHFR 677 genotype is associated with marked MTX-induced hyperhomocysteinemia and could represent a pharmacogenetic marker for toxicity after chronic treatment with low doses of MTX...
  11. doi request reprint Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Pedemontana Occidentale 12, Aviano 33081, Italy
    J Clin Oncol 28:866-71. 2010
    ..Prospective genotype-driven studies should test the efficacy of higher irinotecan doses in the FOLFIRI schedule...
  12. doi request reprint Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy
    Clin Cancer Res 15:3550-6. 2009
    ..The purpose of this study was to investigate the effect of the TP53 Arg72Pro and the MDM2 SNP309 on the risk of osteosarcoma development and survival...
  13. ncbi request reprint The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Medical Oncology unit of Centro di Riferimento Oncologico, National Cancer Institute, Via Pedemontana Occidentale, 12, 33081, Aviano, Italy
    J Clin Oncol 24:3061-8. 2006
    ..UGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, the active metabolite of irinotecan. This could increase toxicity with this agent...
  14. ncbi request reprint Pharmacology of epidermal growth factor inhibitors
    G Toffoli
    Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
    Int J Biol Markers 22:S24-39. 2007
    ....
  15. doi request reprint Pharmacogenetic relevance of MTHFR polymorphisms
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute via Franco Gallini, 2, 33081 Aviano PN, Italy
    Pharmacogenomics 9:1195-206. 2008
    ..Further well-designed studies are needed to clarify the role of MTHFR polymorphisms to derive dose adjustment recommendations on the basis of the patient's genotype...
  16. ncbi request reprint Pharmacogenetics and stomach cancer: an update
    Giuseppe Toffoli
    C R O National Cancer Institute, Experimental and Clinical Pharmacology, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Pharmacogenomics 8:497-505. 2007
    ..A future challenge is represented by the introduction of targeted therapy in gastric cancer treatment, with the potential emerging tool of pharmacogenetic impact on this field...
  17. doi request reprint Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
    Erika Cecchin
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    J Clin Oncol 27:2457-65. 2009
    ..We evaluated the effect of other UGT1A variants and haplotypes involved in 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation on severe toxicity and efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI)...
  18. doi request reprint Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment
    Elena De Mattia
    aExperimental and Clinical Pharmacology Unit bEpidemiology and Biostatistics Unit cMedical Oncology Unit, Centro di Riferimento Oncologico National Cancer Institute, Aviano dMedical Oncology Unit, San Filippo Neri Hospital, Rome eMedical Oncology Unit 1, Istituto Oncologico Veneto IRCCS, Padova, Italy
    Pharmacogenet Genomics 23:549-57. 2013
    ..The aim of this study was to elucidate the predictive/prognostic role of ATP-binding cassette (ABC) and solute carrier (SLC) protein polymorphisms on irinotecan (FOLFIRI regimen) outcome...
  19. ncbi request reprint Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients
    Erika Cecchin
    Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Clin Cancer Res 11:6901-7. 2005
    ....
  20. doi request reprint KIR/HLA combination associated with the risk of complications in celiac disease
    Laura Caggiari
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano Italy
    Int J Biol Markers 26:221-8. 2011
    ..These results suggest that a KIR haplotype and HLA ligands may be involved in the susceptibility to important clinical CD complications such as tumors or refractoriness as a result of a gluten-free diet...
  21. ncbi request reprint UGT1A1*28 polymorphism in ovarian cancer patients
    Erika Cecchin
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, 33081 Aviano, Italy
    Oncol Rep 12:457-62. 2004
    ..In conclusion, the prevalence of UGT1A1*28 found in mucinous OCP could suggest a role in the development of specific histologic sub-groups and could become a marker to be considered when planning ovarian cancer chemotherapy...
  22. doi request reprint Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
    Sergio Frustaci
    Division of Medical Oncology B, National Cancer Institute CRO, Via Franco Gallini, 2, 33081, Aviano, PN, Italy
    Int J Clin Oncol 18:510-6. 2013
    ..A combination of docetaxel (D), oxaliplatin (O), and capecitabine (C) (DOC) was studied in this dose-escalation phase Ib trial in patients with untreated advanced gastric cancer...
  23. doi request reprint C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation
    Elena De Mattia
    Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute, Via Franco Gallini, 2 33081 Aviano PN, Italy
    Eur J Cancer 45:1333-51. 2009
    ..The aim of this review is to critically analyse the available data on the importance of MTHFR polymorphisms in modulating the clinical outcome of antifolate and fluoropyrimidine therapies...
  24. doi request reprint Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy
    Paola Biason
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Franco Gallini 2, 33081 Aviano, Italy
    Pharmacogenomics 13:1609-19. 2012
    ..High levels of TS have been associated with a worse clinical outcome in several cancers including epithelial ovarian cancer (EOC). The TS gene (TYMS) is highly polymorphic and has an effect on mRNA/protein expression...
  25. ncbi request reprint Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases
    Massimo Libra
    Division of Medical Ontology, Centro di Riferimento Oncologico, Aviano, Italy
    Tumori 89:311-3. 2003
    ..Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment...
  26. doi request reprint Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations
    Valli De Re
    Experimental and Clinical Pharmacology Unit, Dipartimento di Oncologia Molecolare e Ricerca Traslazionale, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Franco Gallini, 2, 33081 Aviano PN, Italy
    Ann N Y Acad Sci 1173:152-60. 2009
    ....
  27. ncbi request reprint Pharmacogenetics of stomach cancer
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico CRO, National Cancer Institute, Via Pedemontana Occidentale 12, Aviano, PN
    Suppl Tumori 2:S19-22. 2003
    ..In conclusion, the clinical applications of pharmacogenetics could represent a new insight to accurately determine the proper drug and dose to be used in each individual patient...
  28. ncbi request reprint New oral drugs in older patients: a review of idarubicin in elderly patients
    Diana Crivellari
    Medical Oncology Department, Centro di Riferimento Oncologico, Via Pedemontana Occ, 12, 33081 Aviano, PN, Italy
    Crit Rev Oncol Hematol 49:153-63. 2004
    ..The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed...
  29. pmc Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy
    Massimo Libra
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano, PN, Italy
    BMC Cancer 4:11. 2004
    ..Increased expression of thymidylate synthetase (TS) in CRC metastases has been proposed to be an important mechanism of resistance to fluoropyrimidine-based chemotherapy...
  30. pmc PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage
    Maria Paola Simula
    Experimental and Clinical Pharmacology Unit, CRO Centro diRiferimento Oncologico, IRCCS National Cancer Institute, Aviano PN, Italy
    Mol Med 16:199-209. 2010
    ....
  31. pmc Population pharmacokinetics and pharmacodynamics of oral etoposide
    G Toffoli
    Division of Experimental Oncology 1, Pharmacology Group, Centro di Riferimento Oncologico, National Cancer Center, Aviano, Italy
    Br J Clin Pharmacol 52:511-9. 2001
    ..The population PK model based on creatinine clearance is poorly predictive of exposure. Therapeutic drug monitoring would be necessary for dose individualization or to study the relationship between exposure and antitumour effect...
  32. doi request reprint Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy
    Valli De Re
    Translational Research, CRO National Cancer Institute, IRCCS, Aviano, Pordenone, Italy
    PLoS ONE 9:e84940. 2014
    ....
  33. doi request reprint A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy
    Marica Garziera
    Experimental and Clinical Pharmacology Unit, Department of Molecular Oncology and Translational Medicine, DOMERT, IRCCS, National Cancer Institute, Centro di Riferimento Oncologico, Via F Gallini, 2, 33081, Aviano, PN, Italy
    Clin Exp Med 13:149-57. 2013
    ..In conclusion, the pathogenicity of this mutation is unlikely; probably we found a new germline CDH1 missense mutation with potential impact, however, of uncertain significance...
  34. ncbi request reprint Differential proteomic analysis of hepatocellular carcinoma
    Giuseppe Corona
    Experimental and Clinical Pharmacology Unit, Department of Molecular Oncology and Translational Medicine, Center for Bimolecular Medicine CBM, National Cancer Institute CRO IRCCS, I 33081 Aviano, Italy
    Int J Oncol 36:93-9. 2010
    ..These proteins could represent useful biomarkers to provide new insights into global pathophysiologic changes of HCC and for the development of new pharmacological approaches to HCC therapy...
  35. doi request reprint Galectin-10, eosinophils, and celiac disease
    Valli De Re
    Experimental and Clinical Pharmacology Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Ann N Y Acad Sci 1173:357-64. 2009
    ..Moreover, our data provide insights into alterations associated with CD tissue damage and pathogenesis...
  36. ncbi request reprint Idarubicin
    Diana Crivellari
    Centro di Riferimento Oncologico, Aviano PN
    Tumori 88:S73-4. 2002
  37. doi request reprint High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry
    Giuseppe Corona
    Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano PN, Italy
    Clin Chim Acta 412:358-64. 2011
    ..A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy...
  38. ncbi request reprint MTHFR and ALL risk: a challenge
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute, Aviano, Italy
    Leuk Lymphoma 47:1203-4. 2006
  39. doi request reprint HCV inhibits antigen processing and presentation and induces oxidative stress response in gastric mucosa
    Valli De Re
    Experimental and Clinical Pharmacology, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy
    Proteomics Clin Appl 2:1290-9. 2008
    ..Both these processes facilitate immune escape and cell survival and probably contribute to HCV chronicization...
  40. doi request reprint Metabolomics biomarkers of frailty in elderly breast cancer patients
    Giuseppe Corona
    Experimental and Clinical Pharmacology Division, Department of Translational Research, IRCCS National Cancer Institute, Aviano, PN, Italy
    J Cell Physiol 229:898-902. 2014
    ..Moreover, they might be useful to refine the comprehensive geriatric assessment model. J. Cell. Physiol. 229: 898-902, 2014. © 2013 Wiley Periodicals, Inc. ..
  41. doi request reprint Liquid chromatography tandem mass spectrometry assay for fast and sensitive quantification of estrone-sulfate
    Giuseppe Corona
    National Cancer Institute and Center for Molecular Biomedicine, Aviano, PN, Italy
    Clin Chim Acta 411:574-80. 2010
    ..The aim of this study was to develop a rapid and sensitive liquid chromatography-tandem mass spectrometry assay for the determination of estrone-sulfate, suitable for routine clinical investigations...
  42. ncbi request reprint Identification of proteins associated to multi-drug resistance in LoVo human colon cancer cells
    Michele Visentin
    Experimental and Clinical Pharmacology Unit, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, 33081 Aviano PN, Italy
    Int J Oncol 34:1281-9. 2009
    ..In conclusion, the proteomic approach indicates that multiple mechanisms are simultaneously involved in MDR. These might be useful in the search for new forms of interventional therapeutic approaches for MDR reversal...
  43. ncbi request reprint Carboplatin in elderly patients
    Roberto Sorio
    National Cancer Institute, Aviano PN
    Tumori 88:S35-6. 2002
  44. doi request reprint miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?
    Eva Dreussi
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy
    Pharmacogenomics 13:1635-50. 2012
    ..This review summarizes the most recent and promising results in the field and gives an overview of the future perspective of personalized cancer therapy...
  45. doi request reprint 2-D gel electrophoresis: constructing 2D-gel proteome reference maps
    Maria Paola Simula
    Experimental and Clinical Pharmacology Unit, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Via F Gallini 2, Aviano PN 33081, Italy
    Methods Mol Biol 815:163-73. 2012
    ..The protocol described in this chapter is based on the 2D-DIGE technology and has been applied to obtain the first 2-DE reference map of the human small intestine...
  46. doi request reprint Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype
    Giuseppe Corona
    Experimental and Clinical Pharmacology Division, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy
    Ther Drug Monit 32:638-46. 2010
    ..7% to 13.8% and 3.7% to 13.1%, respectively. The method proved to be robust and suitable for therapeutic drug monitoring as well as for pharmacogenetic-pharmacokinetic correlation studies...
  47. doi request reprint Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies
    Alessandro Pavan
    Department of Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy
    Leuk Lymphoma 49:2048-58. 2008
    ..In this review, the NF-kappaB pathway is suggested as a target for new chemotherapy strategies based on the association of CHOP with molecules more effective than rituximab in this pathway inhibition...
  48. pmc MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer
    Valli De Re
    Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy
    Tumour Biol 31:23-32. 2010
    ..In conclusion, overall findings support the hypothesis that folate plays a role in GC risk. GC-relatives evidence a similar 677TT frequency to that found in the general population...
  49. doi request reprint HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia
    V De Re
    Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy
    Tissue Antigens 75:127-35. 2010
    ..519). Thus, cryoglobulinemia clinical manifestation was found to be correlated with the preferential use of HLA DR-DQ combination in HCV-associated NHL. These data provide new insight into HCV-associated lymphoproliferative pathogenesis...
  50. ncbi request reprint UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity
    P Biason
    Clinical and Experimental Pharmacology Division, CRO Centro di Riferimento Oncologico, National Cancer Unstitute, Aviano, Italy
    J Chemother 20:158-65. 2008
    ..Further prospective studies are required to reach a personalization of chemotherapy with irinotecan...
  51. ncbi request reprint Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study
    R Sorio
    Medical Department, Centro di Riferimento Oncologico, Aviano, Italy
    J Chemother 18:188-91. 2006
    ..The easy self-management, favorable toxicity profile and synergy with other compounds makes oral etoposide suitable for further clinical-pharmacological studies in elderly patients...
  52. ncbi request reprint Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
    D Crivellari
    Division of Medical Oncology C, Centro di Riferimento Oncologico, Aviano, Italy
    Ann Oncol 17:807-12. 2006
    ..To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer...
  53. ncbi request reprint Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma
    G Corona
    Division of Experimental and Clinical Pharmacology, Department of Molecular Oncology and Translational Research, National Cancer Institute, Aviano, Italy
    Clin Pharmacol Ther 83:601-6. 2008
    ..0001) in SN38 AUC in the presence of LPV/RTV. The clinical consequences of these substantial pharmacokinetic changes should be investigated...
  54. doi request reprint Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?
    Elena De Mattia
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Via Franco Gallini, 2, 33081, Aviano, Italy
    Pharmacogenomics 14:2035-54. 2013
    ..In this review, we aim to summarize the most recent findings in the innovative field of NR pharmacogenetics and findings in how they could integrate with more traditional markers in order to improve drug treatment personalization. ..
  55. ncbi request reprint KIR molecules: recent patents of interest for the diagnosis and treatment of several autoimmune diseases, chronic inflammation, and B-cell malignancies
    Valli De Re
    Laboratory of Experimental and Clinical Pharmacology, Department of Molecular Oncology and Translational Medicine DOMERT, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Via F Gallini, 2, 33081 Aviano PN, Italy
    Recent Pat DNA Gene Seq 5:169-74. 2011
    ....
  56. doi request reprint Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets
    Giuseppe Corona
    Experimental and Clinical Pharmacology Division, IRCCS, National Cancer Institute, Aviano, Pordenone, Italy
    J Cell Physiol 227:2827-31. 2012
    ..This review presents the potential role of pharmaco-metabolomics in the future of anticancer pharmacology to achieve customized anticancer treatments and new, targeted therapeutic approaches...
  57. doi request reprint Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometry
    Giuseppe Corona
    Division of Experimental and Clinical Pharmacology, National Cancer Institute and Center for Molecular Biomedicine, Aviano PN, Italy
    Rapid Commun Mass Spectrom 22:519-25. 2008
    ..01% to 6.1%. The proposed assay was found suitable for pharmacokinetics investigations and clinical therapeutic drug monitoring especially in pediatric cancer patients...
  58. doi request reprint Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents
    Michele Visentin
    Experimental and Clinical Pharmacology Unit CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Pharmacol Ther 128:82-90. 2010
    ..Improved molecular characterisation of the EGFR pathway and its complementary pathways in tumor cells is required to better define predictive pharmacokinetic and pharmacodynamic biomarkers for optimum treatment outcome...
  59. doi request reprint A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma
    Giuseppe Corona
    Division of Experimental and Clinical Pharmacology, Department ofMolecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano PN, Italy
    J Mass Spectrom 44:920-8. 2009
    ..5-13.2% and - 9.0-5.8% ranges for Exe and DhExe, respectively. The analytical method resulted robust and suitable for pharmacokinetic monitoring of Exe and its main metabolite during adjuvant therapy in patients with breast cancer...
  60. ncbi request reprint Sarcomas and pharmacogenetics
    Paola Biason
    CRO, National Cancer Institute, Experimental and Clinical Pharmacology, Via Pedemontana Occidentale, 12 33081 Aviano, PN, Italy
    Pharmacogenomics 6:585-601. 2005
    ..For STS and sarcoma of the bone, the genetic markers, which could be unambiguously predictive of the phenotypic profile of patients, are as yet undetermined...
  61. ncbi request reprint High throughput screening of genetic polymorphisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry
    Giuseppe Corona
    Experimental and Clinical Pharmacology Unit, National Cancer Institute, via Pedemontana Occ 12, 33081 Aviano PN Italy
    Comb Chem High Throughput Screen 7:707-25. 2004
    ..In this review, we analyze and discuss in depth the advantages and the limitations of the more recent developments in MALDI-TOF MS analysis for large-scale genomic studies applications...
  62. ncbi request reprint Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit
    M De Cicco
    Department of Anesthesiology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori Centroeuropeo, Aviano, Italy
    Crit Care Med 27:332-9. 1999
    ..Our study aimed at evaluating the pharmacokinetic, cardiovascular, and metabolic effects of high-dose verapamil continuous intravenous infusion in cancer patients...
  63. pmc Two-dimensional gel proteome reference map of human small intestine
    Maria Paola Simula
    Experimental and Clinical Pharmacology, CRO Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Via F, Gallini 2, 33081 Aviano, PN, Italy
    Proteome Sci 7:10. 2009
    ..Spots identifications, reported in a database, will be helpful to identify the variability in protein expression levels, in isoforms expression, or in post-translational modifications associated to pathology or to a therapy...
  64. pmc Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines
    G Toffoli
    Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
    Br J Cancer 63:51-6. 1991
    ....
  65. pmc Pharmacokinetics of doxorubicin co-administered with high-dose verapamil
    M Gigante
    Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
    Br J Cancer 71:134-6. 1995
    ..No significant difference was found between the kinetic parameters estimated for DOX at different levels of VER and those reported for doxorubicin as single agent. It can be concluded that VER does not appear to modify DOX kinetics...
  66. doi request reprint Dissecting Pin1 and phospho-pRb regulation
    Flavio Rizzolio
    Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA
    J Cell Physiol 228:73-7. 2013
    ....
  67. ncbi request reprint Recent patents relating to HCV molecules like putative targets for therapeutic intervention
    Valli De Re
    Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Pordenone, Italy
    Recent Pat DNA Gene Seq 1:186-94. 2007
    ....
  68. ncbi request reprint Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population
    E Cecchin
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy
    Int J Biol Markers 19:160-3. 2004
    ..No significant difference between cases and controls was found. These results do not support a favoring role of CYP1B1*3 in ovarian cancer development in our population...
  69. pmc Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide
    G Toffoli
    Department of Experimental Oncology, Centro di Riferimento Oncologico, Aviano PN, Italy
    Br J Cancer 75:715-21. 1997
    ..CSA affected both the pharmacokinetics and pharmacodynamics of VM26 in the patients, principally by increasing the plasma concentrations of the antineoplastic drug and VM26 haemopoietic toxicity...
  70. ncbi request reprint Frequent occurrence of Ha-rasl allelic deletion in human ovarian adenocarcinomas
    A Viel
    Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
    Tumori 77:16-20. 1991
    ..These findings may suggest that a putative tumor suppressor gene closely linked to Ha-rasl in 11p15.5 is involved in ovarian cancerogenesis...
  71. ncbi request reprint Changes in chemosensitivity of K 562 leukemia cells after induction of erythroid differentiation by hemin
    G Toffoli
    Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Pordenone, Italia
    Tumori 74:11-7. 1988
    ..The results obtained by chemosensitivity tests showed a generalized decrease in chemosensitivity of the K 562 cells to all the drugs tested as a consequence of the hemin-induced differentiation...
  72. ncbi request reprint P-glycoprotein but not topoisomerase II and glutathione-S-transferase-pi accounts for enhanced intracellular drug-resistance in LoVo MDR human cell lines
    M Boiocchi
    Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy
    Tumori 78:159-66. 1992
    ....
  73. ncbi request reprint Is tailored therapy feasible in oncology?
    Giampietro Gasparini
    Division of Medical Oncology, Azienda Complesso Ospedaliero di Rilevanza Nazionale S Filippo Neri Hospital, via G Martinotti 20, 00135 Rome, Italy
    Crit Rev Oncol Hematol 57:79-101. 2006
    ..In addition, further efforts are needed to improve the reliability of genomic and proteomic technologies. These unsolved issues presently make tailored therapy an open challenge...
  74. ncbi request reprint Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease
    Gabriele Stocco
    Department of Biomedical Sciences, University of Trieste, Trieste, Italy
    Dig Dis Sci 51:474-9. 2006
    ..The incidence of mutations in the MTHFR gene was not different between patients with IBD and control subjects; the mutated genotype was not associated with an increased risk of toxicity during thiopurine treatment...
  75. ncbi request reprint Tailored therapy of colorectal cancer: results, challenges and future directions
    Giampietro Gasparini
    Division of Medical Oncology, S Filippo Neri Hospital, Universita Cattolica del Sacro Cuore, Rome, Italy
    Cancer J 11:175-88. 2005
    ..Further efforts are needed to improve the reliability of genomic and proteomic technologies, in particular regarding their standardization and widespread availability. These unsolved issues make tailored therapy an open challenge...
  76. ncbi request reprint Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan
    Giuseppe Corona
    AIDS 19:2043-4. 2005
  77. ncbi request reprint Radiosensitivity in multidrug-resistant and cisplatin-resistant human carcinoma cell lines
    Marco Gigante
    School of Radiotherapy, University of Padua, Padua, Italy
    Am J Clin Oncol 26:e73-9. 2003
    ..The total glutathione content (GSH) of C13 cells was 1.5-fold higher than that of 2008 cells. BSO treatment caused a partial depletion of GSH in 2008 and C13 cells, but their radiosensitivity did not change accordingly...
  78. ncbi request reprint Carboplatin and topotecan combination and myelosuppression
    Giuseppe Toffoli
    J Clin Oncol 20:3558. 2002
  79. doi request reprint Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development
    Valli De Re
    Blood 111:5760. 2008